Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Purpose: To describe and evaluate the main direct health costs, in routine clinical practice, of age-related macular degeneration (AMD) patients, from hospital perspective, in Spain. Methods: Retrospective, multicenter, and observational study conducted on five third-level Spanish hospitals, between December 2018 and December 2019. The study included patients who were diagnosed of AMD before December 2018. Direct healthcare costs were obtained from a Spanish database. Study variables included demographic and clinical variables, and resources, such as treatment, diagnostic tests, medical examination, and surgery. Among the 1414 screened AMD patients, 1164 patients were included. In the overall study patients, the total cost was €5,386,511.0, with a mean cost per patient of €4627.6 ± 2383.9. The largest cost items were diagnostic examinations (€2.832.902,0) and vascular endothelial growth factor inhibitors (anti-VEGF) treatment (€2.038.257,2). Bevacizumab was administered to 325 (27.9%) patients, ranibizumab to 328 (28.2%), and aflibercept to 626 (53.8%); 115 (10.7%) patients received two anti-VEGF treatments, while 90 (7.7%) did not receive any. Over the course of the study, a total of 6,057 anti-VEGF injections were administered, with a mean (95% confidence interval) of 4.8 (4.4–5.2) injections per patient. Regarding safety, 29 patients experience injection-related adverse events, among them 12 patients had cataract and 11 ones elevated intraocular pressure (IOP). The incidence of endophthalmitis was 0.5% (6/1164). Conclusions: AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While direct medical costs were estimated at $9.87 million for a sample of 1,164 patients in the Spanish cost analysis [48], the cross-county study (France, Germany, Italy and the UK), prevalence rates, estimated that costs ranged from $96.56 million to $190.29 million [49], using published prevalence rates.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the Spanish study [48] specified the number of patients with either nAMD (87%), dry AMD (1%) or both (12%) within their sample but did not account for these differences in their reporting of the mean annual ophthalmological-related medical costs ($8,475 per patient).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is worth noting that this study also analysed the use and costs of anti-VEGFs by molecule (bevacizumab, ranibizumab and aflibercept) among the sampled patients and suggested that while ranibizumab was used in only 30% of patients, it represented the highest share of the overall anti-VEGF costs across the patient sample, as opposed to the two other anti-VEGF molecules [48].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Global estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Clinical Classification of Age-related Macular Degeneration
Ferris, F. L., Wilkinson, C. P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K., & Sadda, S. R. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.036 · Cited by 1,863
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Pennington, K. L., & DeAngelis, M. M. (2016) · Eye and Vision · doi:10.1186/s40662-016-0063-5 · Cited by 480
Prevalence of Age-Related Maculopathy in Older Europeans: The European Eye Study (EUREYE)
Augood, C. A. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.4.529 · Cited by 390
ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Brown, D., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., & Kim, R. Y. (2006) · Cited by 382
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Kaiser, P. K., Blodi, B. A., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.04.030 · Cited by 217
AGE-RELATED MACULAR DEGENERATION.
Gheorghe, A., Mahdi, L., & Musat, O. (2015) · PubMed · Cited by 214
The economic impact of sight loss and blindness in the UK adult population
Pezzullo, L., Streatfeild, J., Simkiss, P., & Shickle, D. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2836-0 · Cited by 205
The economic impact and cost of visual impairment in Australia
Taylor, H. R. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.080986 · Cited by 190
Dossarps, D., Bron, A. M., Koehrer, P., Aho-Glélé, L. S., Creuzot-Garcher, C., Berthon, L., Maftouhi, Q.-E., Bakhti, A., Conrath, J., Le Mer, Y., et al. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.013 · Cited by 184
Early and intermediate age-related macular degeneration: update and clinical review
Garcia-Layana, A., Cabrera-López, F., García-Arumí, J., Arias-Barquet, L., & Ruiz-Moreno, J. M. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s142685 · Cited by 178
Self-citationSpain: Country Health Profile 2017
OECD, & Policies, E. O. O. H. S. A. (2017) · State of health in the EU · doi:10.1787/9789264283565-en · Cited by 158
Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., et al. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826010-00006 · Cited by 126
Age‐Related Macular Degeneration
Cheung, L. K., & Eaton, A. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1264 · Cited by 120
van Asten, F., Michels, C. T. J., Hoyng, C. B., van der Wilt, G. J., Klevering, B. J., Rovers, M. M., & Grutters, J. P. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197670 · Cited by 119
Introduction to health economics for the medical practitioner
Kernick, D. P. (2003) · Postgraduate Medical Journal · doi:10.1136/pmj.79.929.147 · Cited by 105
The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates
VanderBeek, B. L., Bonaffini, S. G., & Ma, L. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.07.005 · Cited by 97
Korb, C. A., Kottler, U. B., Wolfram, C., Höhn, R., Schulz, A., Zwiener, I., Wild, P. S., Pfeiffer, N., & Mirshahi, A. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2591-9 · Cited by 92
Safety of 6000 intravitreal dexamethasone implants
Rajesh, B., Zarranz‐Ventura, J., Fung, A. T.-C., Busch, C., Sahoo, N. K., Rodríguez‐Valdés, P. J., Sarao, V., Mishra, S. K., Saatçi, A. O., Udaondo, P., et al. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-313991 · Cited by 85
Self-citationBroadhead, G., Hong, T., & Chang, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12463 · Cited by 61
Prevalence of age-related macular degeneration in Spain
Spanish Eyes Epidemiological (SEE) Study Group (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.187773 · Cited by 55
Carrasco, J., Pietsch, G.-A., Nicolas, M.-P., Koerber, C., Bennison, C., & Yoon, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01147-6 · Cited by 53
Prevalence of Age-related Maculopathy
Klein, R., Klein, R., & Linton, K. L. P. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.033 · Cited by 44
Freiberg, F. J., Brynskov, T., Munk, M. R., Sørensen, T. L., Wolf, S., Wirth, M. A., Becker, M. D., & Michels, S. (2017) · Retina · doi:10.1097/iae.0000000000001488 · Cited by 43
Zapata, M. Á., Arcos, G., Fonollosa, A., Abraldes, M. J., Oléñik, A., Gutiérrez‐Sánchez, E., & García‐Arumí, J. (2016) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2016.0020 · Cited by 34
Self-citationStem, M. S., Todorich, B., Yonekawa, Y., Capone, A., Williams, G. A., & Ruby, A. J. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5883 · Cited by 28
Cidad-Betegón, M. D. P., Armadá-Maresca, F., Santesteban, G. A., Coca-Robinot, J., Mardero, O. D., Rosa-Pérez, I., Manzano-Muñoz, B., García-Martínez, J., Durán, M. A., & Abad, G. C. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1742723 · Cited by 3
Cited by
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1455 · Cited by 61
Buonfiglio, F., Korb, C. A., Stoffelns, B. M., Pfeiffer, N., & Gericke, A. (2024) · Aging and Disease · doi:10.14336/ad.2024.0124 · Cited by 54
Nadeem, A., Malik, I. A., Shariq, F., Afridi, E. K., Taha, M., Raufi, N. K., Naveed, A. K., Iqbal, J., & Habte, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001466 · Cited by 37
“Pegcetacoplan is a medication that was fi rst approved by the FDA in May 2021 to be given as a subcutaneous infusion for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [36] .”
BackgroundMerle, D. A., Provenzano, F., Jarboui, M. A., Kilger, E., Clark, S. J., Deleidi, M., Armento, A., & Ueffing, M. (2021) · Antioxidants · doi:10.3390/antiox10121944 · Cited by 29
“In this light, AMD not only threatens a 54 patient ́s individual quality of life, but also poses a significant burden to health care systems worldwide [7,8].”
BackgroundButler, E. T. S., Arnold‐Vangsted, A., Schou, M. G., Anguita, R., Bjerager, J., Borrelli, E., Cehofski, L. J., Desideri, L. F., van Dijk, E. H. C., Faber, C., et al. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17506 · Cited by 23
“…net surplus for treating neovascular AMD with intravitreal anti-VEGF injections, but the size of the surplus depends on the details of the organization (Abdalla et al., 2024; Neubauer et al., 2010; Quist et al., 2025; Ruiz-Moreno et al., 2021; Sivaprasad et al., 2024; Y ı ld ı r ı m et al., 2018).”
Metadata
- Authors
- Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group
- Affiliations
- Bellvitge University Hospital (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Universitario Río Hortega (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Venue
- International Ophthalmology
- Published
- 2021-06-10
- Volume
- 41
- Issue
- 10
- Pages
- 3427-3436
- ISSN
- 0165-5701 (ISSN-L)
- 1573-2630
- PMC
- PMC8450213
- OpenAlex
- W3170401063
- Cited by
- 41
- References
- 34
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 14 · 2023: 5 · 2022: 2 · 2021: 2
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Ophthalmology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- Funders
- Allergan
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, economic burden, health care costs, anti-VEGF therapy, bevacizumab, ranibizumab, aflibercept, optical coherence tomography, endophthalmitis, cataract, intraocular pressure, hospital costs
- MeSH terms
- Bevacizumab, Ranibizumab, Humans, Macular Degeneration, Recombinant Fusion Proteins, Retrospective Studies, Visual Acuity, Cost of Illness, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


